Background—Chagas disease remains a significant public health issue and a major cause
of morbidity and mortality in Latin America. Despite nearly 1 century of research, the …

Chagas disease, caused by the protozoan Trypanosoma cruzi, is endemic in Latin America
and affects ca. 10 million people worldwide. About 30% of Chagas disease patients develop …

Trypanosoma cruzi interacts with the different arms of the innate and adaptive host's immune
response in a very complex and flowery manner. The history of host-parasite co-evolution …

Abstract The adenovirus type 5 (Ad5)-based vaccine developed by Merck failed to either
prevent HIV-1 infection or suppress viral load in subsequently infected subjects in the STEP …

Innate and adaptive cellular immune recognition is crucial for control of the protozoan
parasite Trypanosoma cruzi. T. cruzi triggers both MyD88-dependent and TRIF-dependent …

CD8+ T cells are crucial for control of a number of medically important protozoan parasites,
including Trypanosoma cruzi, the agent of human Chagas disease. Yet, in contrast to the …

Trypanosoma cruzi (T. cruzi) is the causative agent for Chagas disease (CD). There is a
critical lack of methods for prevention of infection or treatment of acute infection and chronic …

Background Chronic Chagas cardiomyopathy (CCC), a life-threatening inflammatory dilated
cardiomyopathy, affects 30% of the approximately 8 million patients infected by …

Up to 18 million of individuals are infected by the protozoan parasite Trypanosoma cruzi in
Latin America, one third of whom will develop chronic Chagas disease cardiomyopathy …

This review aims to present different aspects related to cruzipain, one of the most important
proteins of the etiological agent of Chagas disease that has been extensively studied in the …